A pivotal trial investigating docetaxel emulsion [ANX 514; Adventrx Pharmaceuticals] without corticosteriod premedication, compared with docetaxel [Taxotere; sanofi-aventis] with corticosteroid premedication, in patients with non-small cell lung cancer that has failed prior platinum-based therapy.

Trial Profile

A pivotal trial investigating docetaxel emulsion [ANX 514; Adventrx Pharmaceuticals] without corticosteriod premedication, compared with docetaxel [Taxotere; sanofi-aventis] with corticosteroid premedication, in patients with non-small cell lung cancer that has failed prior platinum-based therapy.

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2011

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 27 Oct 2011 ADVENTRX and the US FDA have met to discuss the trial, and agree that it will provide sufficient clinical data to support approval of the docetaxel emulsion (ANX 514), according to an ADVENTRX media release. The company expects to fline and NDA in 2014.
    • 03 Oct 2011 Planned initiation date changed to 1 Jan 2012, according to an ADVENTRX Pharmaceuticals media release.
    • 28 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top